MX9702259A - Derivados de quinoxalina utiles en terapia. - Google Patents

Derivados de quinoxalina utiles en terapia.

Info

Publication number
MX9702259A
MX9702259A MX9702259A MX9702259A MX9702259A MX 9702259 A MX9702259 A MX 9702259A MX 9702259 A MX9702259 A MX 9702259A MX 9702259 A MX9702259 A MX 9702259A MX 9702259 A MX9702259 A MX 9702259A
Authority
MX
Mexico
Prior art keywords
therapy
derivatives useful
quinoxaline derivatives
alkyl
cycloalkyl
Prior art date
Application number
MX9702259A
Other languages
English (en)
Inventor
Michael Jonathan Fray
Charles Eric Mowbray
Alan Stobie
Original Assignee
Pfizer Res & Dev
Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev, Sa filed Critical Pfizer Res & Dev
Publication of MX9702259A publication Critical patent/MX9702259A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuesto de la formula (I) en laque A representa N o CH; R1 y R2 independientemente representan alquilo C1-4, halogeno o CF3; R3 representa alquilo C1-4 (opcionalmente sustituido), cicloalquilo C3-7, CF3, o arilo; y R4 representa H, cicloalquilo C3-7 o alquilo C1-6 (opcionalmente sustituido); y sus derivados farmacéuticamente aceptables utiles en el tratamiento de, entre otros, trastornos neurodegerativos. (Ver Formula).
MX9702259A 1994-09-24 1995-09-08 Derivados de quinoxalina utiles en terapia. MX9702259A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9419318A GB9419318D0 (en) 1994-09-24 1994-09-24 Therapeutic agents
PCT/EP1995/003559 WO1996009295A1 (en) 1994-09-24 1995-09-08 Quinoxaline derivatives useful in therapy

Publications (1)

Publication Number Publication Date
MX9702259A true MX9702259A (es) 1997-06-28

Family

ID=10761869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702259A MX9702259A (es) 1994-09-24 1995-09-08 Derivados de quinoxalina utiles en terapia.

Country Status (28)

Country Link
US (1) US5852016A (es)
EP (1) EP0783495B1 (es)
JP (1) JP2986920B2 (es)
KR (1) KR970706261A (es)
CN (1) CN1158610A (es)
AT (1) ATE213731T1 (es)
AU (1) AU688591B2 (es)
BR (1) BR9504132A (es)
CA (1) CA2200742C (es)
CO (1) CO4410336A1 (es)
CZ (1) CZ85797A3 (es)
DE (1) DE69525633T2 (es)
DK (1) DK0783495T3 (es)
ES (1) ES2171553T3 (es)
FI (1) FI971193A (es)
GB (1) GB9419318D0 (es)
HU (1) HUT77734A (es)
IL (2) IL115334A0 (es)
MX (1) MX9702259A (es)
NO (1) NO971261L (es)
NZ (1) NZ292922A (es)
PE (1) PE47596A1 (es)
PL (1) PL319405A1 (es)
PT (1) PT783495E (es)
RU (1) RU2135484C1 (es)
TR (1) TR199501158A2 (es)
WO (1) WO1996009295A1 (es)
ZA (1) ZA958023B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
DE69619088T2 (de) * 1995-10-10 2002-07-11 Pfizer Quinoxalin-Derivate zur Behandlung von Tinnitus
GB9604400D0 (en) 1996-03-01 1996-05-01 Pfizer Ltd Compounds useful in therapy
AU3133697A (en) 1996-06-05 1998-01-05 Warner-Lambert Company Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
EP0963372A1 (en) * 1997-02-18 1999-12-15 American Home Products Corporation 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists
US5922715A (en) * 1997-02-18 1999-07-13 American Home Products Corporation 5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
US10208000B2 (en) 2015-12-16 2019-02-19 University Of Kentucky Research Foundation Eis inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE572852C (de) * 1931-03-08 1933-03-24 Willy Messerschmitt Dipl Ing Verfahren zur Herstellung von Flugzeugtragfluegeln mit trapezfoermigem Grundriss
DK146787A (da) * 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
DK715888D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
JP2550456B2 (ja) * 1990-11-06 1996-11-06 山之内製薬株式会社 縮合ピラジン誘導体
DE4123106A1 (de) * 1991-07-09 1993-01-14 Schering Ag Arzneimittel zur behandlung von entzugssymptomen
PT101004B (pt) * 1991-10-26 1999-10-29 Schering Ag Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
WO1994000124A1 (en) * 1992-06-22 1994-01-06 Eckard Weber Glycine receptor antagonists and the use thereof
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE4439493A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US5614508A (en) * 1995-06-07 1997-03-25 Warner-Lambert Company Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists

Also Published As

Publication number Publication date
PL319405A1 (en) 1997-08-04
DK0783495T3 (da) 2002-04-22
BR9504132A (pt) 1996-08-06
JPH09511526A (ja) 1997-11-18
TR199501158A2 (tr) 1997-02-21
IL126104A0 (en) 1999-05-09
CA2200742A1 (en) 1996-03-28
AU688591B2 (en) 1998-03-12
PE47596A1 (es) 1996-11-12
NO971261D0 (no) 1997-03-19
DE69525633T2 (de) 2002-08-08
DE69525633D1 (de) 2002-04-04
CO4410336A1 (es) 1997-01-09
ZA958023B (en) 1997-03-24
ATE213731T1 (de) 2002-03-15
PT783495E (pt) 2002-07-31
GB9419318D0 (en) 1994-11-09
IL115334A0 (en) 1995-12-31
WO1996009295A1 (en) 1996-03-28
AU3523295A (en) 1996-04-09
JP2986920B2 (ja) 1999-12-06
US5852016A (en) 1998-12-22
EP0783495A1 (en) 1997-07-16
EP0783495B1 (en) 2002-02-27
HUT77734A (hu) 1998-07-28
NO971261L (no) 1997-05-05
CA2200742C (en) 2001-09-11
ES2171553T3 (es) 2002-09-16
FI971193A (fi) 1997-05-21
NZ292922A (en) 1998-07-28
RU2135484C1 (ru) 1999-08-27
CZ85797A3 (cs) 1998-09-16
CN1158610A (zh) 1997-09-03
FI971193A0 (fi) 1997-03-21
KR970706261A (ko) 1997-11-03

Similar Documents

Publication Publication Date Title
BG106586A (en) Pyrazolopyramidines as therapeutic agents
MY110110A (en) Pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and cns disorders
MY103352A (en) Piperazinyl-heterocyclic compounds
TR199801642T2 (xx) Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri.
MX9701292A (es) Compuestos espiro-azabiciclicos utiles en la terapia.
MX9605915A (es) Derivados de piperazina como antagonistas de 5ht1a.
IL119207A0 (en) Treatment of tinnitus using neuroprotective agents
MX9702259A (es) Derivados de quinoxalina utiles en terapia.
GB9310095D0 (en) Therapeutic compounds
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
DK0428313T3 (da) Pyrimidonderivater samt analoge til behandling af astma og visse hudlidelser
NO20003211L (no) Triazinforbindelser for behandling av CNS forstyrrelser
AU670491C (en) Pharmaceutical for the treatment of skin disorders
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
PL345966A1 (en) N-substituted azabicycloheptane derivatives, production and use thereof
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
ECSP951538A (es) Derivados de quinoxalina utiles en terapia

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: PFIZER IRELAND PHARMACEUTICALS

MM Annulment or lapse due to non-payment of fees